• share
• favorite_border

Positive trends in global education access are expected to decrease dementia prevalence worldwide by 6.2 million cases by the year 2050.

• share
• favorite_border

On behalf of all those living with Alzheimer's disease, their caregivers, and their families, we appreciate the Centers for Medicare & Medicaid Services (CMS) thoughtful consideration on coverage considerations for monoclonal antibodies targeting amyloid for the treatment of Alzheimer's disease, including aducanumab, which was recently approved by the Food and Drug Administration (FDA).

• share
• favorite_border

Aduhelm has been approved for use for those with Mild Cognitive Impairment or early stage Alzheimer's dementia. This treatment offers a marginal but potentially meaningful slowing of decline for this subpopulation of individuals with Alzheimer's disease, a terminal disease with no survivors. Though approved, access to the treatment is at risk of being impeded by significant barriers which may further deepen issues of health equity.

• share
• favorite_border

The Alzheimer's Association is pleased with the announcement today that the Food and Drug Administration (FDA) has revised the prescribing label for Aduhelm™ (aducanumab).

• share
• favorite_border

As the global nonprofit leader in Alzheimer's research and science we have extensively reviewed the clinical trial data for Aduhelm™ (aducanumab).

• share
• favorite_border

This is the first drug that slows Alzheimer's disease. And, this is the beginning of a completely new future for Alzheimer's treatments. This is a new type of Alzheimer's treatment; it addresses the disease in a way that has never been done before, compared to currently approved drugs. Alzheimer's Association spokespeople are available.

• share
• favorite_border

• share
• favorite_border

The forthcoming 2021 Alzheimer’s Association Facts & Figures Report, as well as a new supplemental report “Race, Ethnicity and Alzheimer’s in America,” will be released March 2. Facts and Figures provides in-depth information on Alzheimer’s and other dementias in the U.S., including the latest stats on prevalence, mortality, costs, caregiving and other insights both nationally and with state by state data.

• share
• favorite_border

A simple blood test for Alzheimer’s would be a great advance for individuals with — and at risk for — the disease, families, doctors and researchers.

• share
• favorite_border

• share
• favorite_border

- Report provides latest Alzheimer’s prevalence, incidence, mortality and costs of care data - - Barring medical breakthroughs, the number of people age 65+ with Alzheimer’s dementia may nearly triple by 2050 -

• share
• favorite_border

The Alzheimer’s Association will issue the 2020 Alzheimer’s Diseases Facts and Figures Report on March 11, 2020. The new report will highlight the latest disease-related statistics for America’s 6th leading cause of death for those 65+, including prevalence, incidence, mortality, costs of care and impact on caregivers both nationally, as well as state by state data, for both 2020 and future projections. This new report will feature findings from a first-of-its-kind, comprehensive survey of primary care physicians (PCPs) and medical school residents which examines the medical profession’s readiness to meet future care needs for the growing number of people living with Alzheimer’s and other dementias. Information and report findings are under strict embargo until Wednesday, March 11, 2020.

• share
• favorite_border

New research published by the journal Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring confirms the connection between posttraumatic stress disorder (PTSD) and cognitive impairment - in this case, among those who helped with search, rescue and cleanup efforts following the 2001 World Trade Center (WTC) attacks.